Covid-19 Nasal Spray Study

A nasal spray administered in high-risk adult Covid patients in India reduced viral load by 94% within 24 hours and 99% in 48 hours, according to the results of phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.

A nasal spray administered in high-risk adult Covid patients in India reduced viral load by 94% within 24 hours and 99% in 48 hours, according to the results of phase 3 trial of the drug published in The Lancet Regional Health Southeast Asia journal.